Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197767
Max Phase: Preclinical
Molecular Formula: C17H13N5O2
Molecular Weight: 319.32
Associated Items:
ID: ALA5197767
Max Phase: Preclinical
Molecular Formula: C17H13N5O2
Molecular Weight: 319.32
Associated Items:
Canonical SMILES: C=CCn1cc(C#N)c2cc(NC(=O)c3cc(=O)[nH]cn3)ccc21
Standard InChI: InChI=1S/C17H13N5O2/c1-2-5-22-9-11(8-18)13-6-12(3-4-15(13)22)21-17(24)14-7-16(23)20-10-19-14/h2-4,6-7,9-10H,1,5H2,(H,21,24)(H,19,20,23)
Standard InChI Key: KHPTWYOLSQNVOZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 319.32 | Molecular Weight (Monoisotopic): 319.1069 | AlogP: 2.03 | #Rotatable Bonds: 4 |
Polar Surface Area: 103.57 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.36 | CX Basic pKa: | CX LogP: 1.41 | CX LogD: 1.37 |
Aromatic Rings: 3 | Heavy Atoms: 24 | QED Weighted: 0.72 | Np Likeness Score: -1.83 |
1. Zhang B, Duan Y, Yang Y, Mao Q, Lin F, Gao J, Dai X, Zhang P, Li Q, Li J, Dai R, Wang S.. (2022) Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors., 227 [PMID:34688012] [10.1016/j.ejmech.2021.113928] |
Source(1):